Ming Yi, Ronald J. Podhajsky, et al.
SPIE Photonics West BiOS 2011
For nearly 40 years, drug dossiers have supported the quality, safety and risk/benefits of medicinal products - essentially becoming the passport that every drug requires to enter the market. However, because of changing market conditions and the increasing policy of cost-containment, a good drug dossier, with its duly compiled quality, safety and efficacy reports, is no longer sufficient. Thus the traditional drug dossier will soon be replaced some day by compounded e-documents, submitted in XML format, reviewed and approved on-line by the regulators, under the scrutiny of patient groups and with the final blessing of governmental and private payers.
Ming Yi, Ronald J. Podhajsky, et al.
SPIE Photonics West BiOS 2011
Wilhad Reuter, Allen Lurio
Nuclear Instruments and Methods
Alex Golts, Daniel Khapun, et al.
MICCAI 2021
T. Barsalou, W. Sujansky, et al.
Computers and Biomedical Research